<DOC>
	<DOCNO>NCT00171951</DOCNO>
	<brief_summary>Cushing 's disease rare serious condition cause adrenocorticotropic hormone ( ACTH ) secrete pituitary adenoma . This study assess long-term safety efficacy pasireotide patient Cushing 's disease .</brief_summary>
	<brief_title>Extension Study Assess Safety Efficacy Pasireotide Patients With Cushing 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<criteria>Patients complete 15 day Pasireotide treatment CSOM230B2208 study achieve normalization 24hour urinary free cortisol . Patients achieve normalization 24 hour urinary free cortisol may enrol opinion investigator patient get significant clinical benefit treatment Pasireotide . The patient experience unacceptable adverse event tolerability issue original 15 day treatment . Female patient child bear potential undergone clinically document total hysterectomy and/or ovariectomy , tubal ligation must agree use barrier contraception throughout course extension study , one month study end Patients develop poorly control diabetes mellitus indicated ketoacidosis HgbA1C &gt; 10 since start [ study CSOM230B2208 ] Patients persistent ALT/AST alkaline phosphatase level 2.5X ULN , serum creatinine &gt; 2.0 X ULN , serum bilirubin &gt; 2 X ULN Patients abnormal coagulation ( PT PTT elevate 30 % normal limit ) , WBC &lt; 3.0x1'000'000'000/L ; Hgb &lt; 12.0g/dL female , Hgb &lt; 13.0g/dL male ; PLT &lt; 100x1'000'000'000/L Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Cushing 's disease</keyword>
	<keyword>ACTH</keyword>
	<keyword>Cortisol</keyword>
	<keyword>ACTH dependent Cushing 's disease</keyword>
</DOC>